Natco Pharma gets EIR from USFDA for Telangana facility
The United States Food and Drug Administration (USFDA) had conducted pre-approval inspection at the company's drug formulations facility in Kothur village during the period from March 2 to 6, 2020, Natco Pharma said in a filing to the BSE.
By PTI | Updated:
New Delhi: Drug firm Natco Pharma on Saturday said it has received establishment inspection report (EIR) from the US health regulator for its Kothur facility in Telangana.
The United States Food and Drug Administration (USFDA) had conducted pre-approval inspection at the company's drug formulations facility in Kothur village during the period from March 2 to 6, 2020, Natco Pharma said in a filing to the BSE.
The EIR signifies successful closure of inspection by the regulator, it added.
The United States Food and Drug Administration (USFDA) had conducted pre-approval inspection at the company's drug formulations facility in Kothur village during the period from March 2 to 6, 2020, Natco Pharma said in a filing to the BSE.
The EIR signifies successful closure of inspection by the regulator, it added.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
Related Articles
Telangana: Rajnath Singh advises cadets to "Adapt, Adopt, Amend" at Combined Graduation Parade ceremonyADVERTISEMENT
